Treace Medical Q2 revenue edges above estimates

Reuters

Aug 08

Treace Medical <a href="https://laohu8.com/S/QTWO">Q2</a> revenue edges above estimates

Overview

Treace Medical Q2 2025 revenue rises 7%, beating analyst expectations, per LSEG data
Net loss improved by 18% to $17.4 mln, adjusted EBITDA loss reduced by 58%
Expanded bunion technology portfolio with new systems and increased patent holdings

Outlook

Treace reaffirms 2025 revenue guidance of $224 mln to $230 mln
Company expects breakeven Adjusted EBITDA for full-year 2025
Treace projects 50% reduction in cash usage for 2025

Result Drivers

TECHNOLOGY EXPANSION - Release of Nanoplasty, Percuplasty, and SpeedMTP systems contributed to revenue growth
OPERATING EFFICIENCIES - Reduction in operating expenses helped improve net loss figures

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Revenue	Beat	$47.39 mln	$47.10 mln (6 Analysts)
Q2 EPS		-$0.28
Q2 Gross Margin		79.7%
Q2 Gross Profit		$37.75 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Treace Medical Concepts Inc is $9.00, about 39.2% above its August 6 closing price of $5.47

Press Release: ID:nGNXbhyGfy

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2557594646"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557594646\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557594646?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-08 05:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557594646","market":"nz","top_or_hot":-1,"title":"Treace Medical Q2 revenue edges above estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Treace Medical <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue edges above estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Treace Medical Q2 2025 revenue rises 7%, beating analyst expectations, per LSEG data</p></li><li><p>Net loss improved by 18% to $17.4 mln, adjusted EBITDA loss reduced by 58%</p></li><li><p>Expanded bunion technology portfolio with new systems and increased patent holdings</p></li></ul><p><span>Outlook</span></p><ul><li><p>Treace reaffirms 2025 revenue guidance of $224 mln to $230 mln</p></li><li><p>Company expects breakeven Adjusted EBITDA for full-year 2025</p></li><li><p>Treace projects 50% reduction in cash usage for 2025</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>TECHNOLOGY EXPANSION - Release of Nanoplasty, Percuplasty, and SpeedMTP systems contributed to revenue growth</p></li><li><p>OPERATING EFFICIENCIES - Reduction in operating expenses helped improve net loss figures</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td><p>Beat</p></td><td><p>$47.39 mln</p></td><td><p>$47.10 mln (6 Analysts)</p></td></tr><tr><td><p>Q2 EPS</p></td><td></td><td><p>-$0.28</p></td><td></td></tr><tr><td><p>Q2 Gross Margin</p></td><td></td><td><p>79.7%</p></td><td></td></tr><tr><td><p>Q2 Gross Profit</p></td><td></td><td><p>$37.75 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", 4 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Treace Medical Concepts Inc is $9.00, about 39.2% above its August 6 closing price of $5.47</p></li></ul><p>Press Release: <span>ID:nGNXbhyGfy</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Treace Medical Q2 revenue edges above estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTreace Medical Q2 revenue edges above estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-08 05:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Treace Medical <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue edges above estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Treace Medical Q2 2025 revenue rises 7%, beating analyst expectations, per LSEG data</p></li><li><p>Net loss improved by 18% to $17.4 mln, adjusted EBITDA loss reduced by 58%</p></li><li><p>Expanded bunion technology portfolio with new systems and increased patent holdings</p></li></ul><p><span>Outlook</span></p><ul><li><p>Treace reaffirms 2025 revenue guidance of $224 mln to $230 mln</p></li><li><p>Company expects breakeven Adjusted EBITDA for full-year 2025</p></li><li><p>Treace projects 50% reduction in cash usage for 2025</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>TECHNOLOGY EXPANSION - Release of Nanoplasty, Percuplasty, and SpeedMTP systems contributed to revenue growth</p></li><li><p>OPERATING EFFICIENCIES - Reduction in operating expenses helped improve net loss figures</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td><p>Beat</p></td><td><p>$47.39 mln</p></td><td><p>$47.10 mln (6 Analysts)</p></td></tr><tr><td><p>Q2 EPS</p></td><td></td><td><p>-$0.28</p></td><td></td></tr><tr><td><p>Q2 Gross Margin</p></td><td></td><td><p>79.7%</p></td><td></td></tr><tr><td><p>Q2 Gross Profit</p></td><td></td><td><p>$37.75 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", 4 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Treace Medical Concepts Inc is $9.00, about 39.2% above its August 6 closing price of $5.47</p></li></ul><p>Press Release: <span>ID:nGNXbhyGfy</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TMCI","symbol_name":"Treace Medical Concepts, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nPLX982999:2","article_id":"2557594646","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557594646","pubTimestamp":1754602258,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Treace Medical Q2 revenue edges above estimatesOverviewTreace Medical Q2 2025 revenue rises 7%, beating analyst expectations, per LSEG dataNet loss improved by 18% to $17.4 mln, adjusted EBITDA loss r","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TMCI":"Treace Medical Concepts, Inc."},"translate_title":"Treace Medical第二季度收入略高于预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TMCI":0.9},"content_text":"Treace Medical Q2 revenue edges above estimatesOverviewTreace Medical Q2 2025 revenue rises 7%, beating analyst expectations, per LSEG dataNet loss improved by 18% to $17.4 mln, adjusted EBITDA loss reduced by 58%Expanded bunion technology portfolio with new systems and increased patent holdingsOutlookTreace reaffirms 2025 revenue guidance of $224 mln to $230 mlnCompany expects breakeven Adjusted EBITDA for full-year 2025Treace projects 50% reduction in cash usage for 2025Result DriversTECHNOLOGY EXPANSION - Release of Nanoplasty, Percuplasty, and SpeedMTP systems contributed to revenue growthOPERATING EFFICIENCIES - Reduction in operating expenses helped improve net loss figuresKey DetailsMetricBeat/MissActualConsensus EstimateQ2 RevenueBeat$47.39 mln$47.10 mln (6 Analysts)Q2 EPS-$0.28Q2 Gross Margin79.7%Q2 Gross Profit$37.75 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", 4 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the medical equipment, supplies & distribution peer group is \"buy\"Wall Street's median 12-month price target for Treace Medical Concepts Inc is $9.00, about 39.2% above its August 6 closing price of $5.47Press Release: ID:nGNXbhyGfy(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}